Active — Not RecruitingNot Applicable

the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARtery DIseAse Study

3,000 participantsStarted 2013-10

Plain-language summary

The goal of this observational study is to explore the relationship between biological aging and long-term prognosis of patients with metabolic cardiovascular disease in premature coronary artery disease. The main question\[s\] it aims to answer \[is/are\]: 1. Do patients with premature coronary heart disease have accelerated biological aging? 2. What is the prognosis of accelerated biological aging in patients with premature coronary heart disease?

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female inpatients over 18 years old in the Department of Cardiovascular Medicine; * Patients with one of the following metabolic cardiovascular diseases \[17\]: including diabetes, hypertension, coronary heart disease, heart failure, cerebral infarction, dyslipidemia, obesity and hyperuricemia; * Those who have corresponding inspection data so as to be able to calculate the biological age; * Obtaining oral informed consent or signing an informed consent form; Exclusion Criteria: ·NA

What they're measuring

International physical activity questionnaire

Timeframe: Baseline.

Accelerometer

Timeframe: Up to 8 weeks.

Cardiopulmonary test

Timeframe: Up to 8 weeks.

Glucose

Timeframe: Up to 8 weeks.

Hemoglobin A1c (HbA1c)

Timeframe: Up to 8 weeks.

Serum creatinine

Timeframe: Up to 8 weeks.

Lipid

Timeframe: Up to 8 weeks.

Serum uric acid

Timeframe: Up to 8 weeks.

Blood urea nitrogen

Timeframe: Up to 8 weeks.

Trial details

NCT IDNCT06695182

SponsorSun Yat-sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-11

View on ClinicalTrials.gov More Premature Coronary Heart Disease trials